We are proud to see two of our portfolio companies, ShanX Medtech BV Medtech and VivArt-X, selected for the first-ever TMC Netherlands BioBridge program 2026.
The program connects Dutch medtech innovation with the U.S. healthcare market, providing access to the Texas Medical Center in Houston, its leading hospitals, and a strong network of clinicians, researchers, mentors, investors and healthcare decision-makers.
For ShanX and VivArt-X, this is an important opportunity to further test, refine and scale their plans for the U.S. market alongside other promising Dutch medtech innovators.
Congratulations to ShanX Medtech BV, VivArt-X and all other selected companies!